Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 5/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843896 | 0.84 | TOP2A (0.38) | TOP2AHSP90AB1FURIN | |
| SCHEMBL2873210 | 0.82 | UTS2R (0.37) | OPRD1SLC6A3 | |
| SCHEMBL2844559 | 0.77 | OPRD1 (0.37) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2841128 | 0.75 | TOP2A (0.36) | TOP2AHSP90AB1FURINSLC6A2SLC6A4 | |
| SCHEMBL3583019 | 0.73 | SLC6A2 (0.47) | HTR2AHTR2CHTR2BOPRD1SLC6A2 | |
| SCHEMBL2841048 | 0.70 | HTR2C (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL2835996 | 0.70 | SLC6A2 (0.35) | TOP2AHSP90AB1FURINSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2839430 | 0.69 | UTS2R (0.37) | OPRD1 | |
| SCHEMBL2845450 | 0.69 | DRD1 (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL2836825 | 0.68 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | TOP2A 2958/4885HSP90AB1 446/4885HTR2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.